PDCD1 and neoplasm: Like IFNγ, the anti–VEGF-ANG2 antibody upregulates immune inhibitory molecules such as PD-L1 on both ECs and tumor cells to promote T-cell exhaustion, highlighting the benefit of co-treatment with anti–PD-1 antibody (61).